StockNews.com Initiates Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)

Equities research analysts at StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Free Report) in a report issued on Tuesday. The brokerage set a “hold” rating on the stock.

BiondVax Pharmaceuticals Price Performance

Shares of BVXV stock opened at $1.30 on Tuesday. The stock has a market cap of $2.43 million, a price-to-earnings ratio of -0.51 and a beta of 2.37. The business’s fifty day moving average is $1.39 and its 200 day moving average is $1.85. BiondVax Pharmaceuticals has a twelve month low of $1.29 and a twelve month high of $12.70.

Get BiondVax Pharmaceuticals alerts:

BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Free Report) last released its earnings results on Monday, May 15th. The company reported ($1.20) EPS for the quarter. Equities research analysts expect that BiondVax Pharmaceuticals will post -0.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its holdings in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Free Report) by 226.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 163,423 shares of the company’s stock after purchasing an additional 113,418 shares during the quarter. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 20.88% of the stock is currently owned by institutional investors and hedge funds.

BiondVax Pharmaceuticals Company Profile

(Get Free Report)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

Featured Stories

• Five stocks we like better than BiondVax Pharmaceuticals
• The How And Why of Investing in Oil Stocks
• 3 Sizzling Dividends That Are Going On Sale
• Pros And Cons Of Monthly Dividend Stocks
• 3 Ways To Trade, Trade Desk Stock Post Earnings
• How to Start Investing in Penny Stocks
• Inflation, The Fed, and Oil Prices: Interest Rates Are Going Up

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.